EP2094861A4 - Processus de traitement thérapeutique personnalisé - Google Patents

Processus de traitement thérapeutique personnalisé

Info

Publication number
EP2094861A4
EP2094861A4 EP07864570A EP07864570A EP2094861A4 EP 2094861 A4 EP2094861 A4 EP 2094861A4 EP 07864570 A EP07864570 A EP 07864570A EP 07864570 A EP07864570 A EP 07864570A EP 2094861 A4 EP2094861 A4 EP 2094861A4
Authority
EP
European Patent Office
Prior art keywords
treatment process
therapeutic treatment
personalized therapeutic
personalized
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07864570A
Other languages
German (de)
English (en)
Other versions
EP2094861A2 (fr
Inventor
Ali Arjomand
Glenn Kawasaki
Michael Chansler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accium Biosciences
Original Assignee
Accium Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accium Biosciences filed Critical Accium Biosciences
Publication of EP2094861A2 publication Critical patent/EP2094861A2/fr
Publication of EP2094861A4 publication Critical patent/EP2094861A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP07864570A 2006-11-17 2007-11-17 Processus de traitement thérapeutique personnalisé Withdrawn EP2094861A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85973906P 2006-11-17 2006-11-17
PCT/US2007/085033 WO2008064138A2 (fr) 2006-11-17 2007-11-17 Processus de traitement thérapeutique personnalisé

Publications (2)

Publication Number Publication Date
EP2094861A2 EP2094861A2 (fr) 2009-09-02
EP2094861A4 true EP2094861A4 (fr) 2010-03-17

Family

ID=39430529

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07864570A Withdrawn EP2094861A4 (fr) 2006-11-17 2007-11-17 Processus de traitement thérapeutique personnalisé

Country Status (7)

Country Link
EP (1) EP2094861A4 (fr)
JP (1) JP2010510495A (fr)
CN (1) CN101702921A (fr)
AU (1) AU2007323782A1 (fr)
BR (1) BRPI0719314A2 (fr)
CA (1) CA2669864A1 (fr)
WO (1) WO2008064138A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0714040D0 (en) * 2007-07-19 2007-08-29 Xceleron Ltd Quantification of analytes
CN105467108A (zh) * 2015-12-19 2016-04-06 开滦总医院 溶栓药物个体化应用剂量的体外测定试验方法
US20200116657A1 (en) * 2018-10-15 2020-04-16 Olaris, Inc. Nmr-metabolite-signature for identifying cancer patients resistant to cdk4/6 inhibitors, endocrine therapy and anti-her2 therapy
EP4046161A4 (fr) * 2019-10-18 2023-11-29 National University of Singapore Procédé de prédiction d'une thérapie appropriée

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092584A2 (fr) * 2005-03-02 2006-09-08 Xceleron Limited Compositions biologiques marquees au moyen d'un radio-isotope

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131544A (en) * 1976-08-03 1978-12-26 Nasik Elahi Macroencapsulated sorbent element and process for using the same
US4880014A (en) * 1987-08-14 1989-11-14 Zarowitz Barbara J Method for determining therapeutic drug dosage using bioelectrical resistance and reactance measurements
GB0304433D0 (en) * 2003-02-27 2003-04-02 Xceleron Ltd Improvements relating to chemical libraries
JP2006523457A (ja) * 2003-04-02 2006-10-19 セレーター ファーマスーティカルズ、インク． コンビネーション治療の個別化方法
US7662097B2 (en) * 2004-09-20 2010-02-16 Resonant Medical, Inc. Radiotherapy treatment monitoring using ultrasound
US7439498B2 (en) * 2004-10-28 2008-10-21 Albert Edward Litherland Method and apparatus for separation of isobaric interferences

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092584A2 (fr) * 2005-03-02 2006-09-08 Xceleron Limited Compositions biologiques marquees au moyen d'un radio-isotope

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BEUMER J ET AL: "Mass balance studies, with a focus on anticancer drugs", CLINICAL PHARMACOKINETICS, ADIS INTERNATIONAL LTD., AUCKLAND, NZ, vol. 45, no. 1, 1 January 2006 (2006-01-01), pages 33 - 58, XP008097093, ISSN: 0312-5963 *
DEGREGORIO M W ET AL: "Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 57, no. 3, 1 March 2006 (2006-03-01), pages 335 - 342, XP019334309, ISSN: 1432-0843 *
DINGLEY K H ET AL: "Picogram detection of doxorubicin in breast cancer cells using accelerator mass spectrometry", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 45, 31 March 2004 (2004-03-31), pages 121, XP008113675, ISSN: 0197-016X *
KAREN H. DINGLEY ET AL: "Attomole Detection of 3 H in Biological Samples Using Accelerator Mass Spectrometry: Application in Low-Dose, Dual-Isotope Tracer Studies in Conjunction with 14 C Accelerator Mass Spectrometry", CHEMICAL RESEARCH IN TOXICOLOGY, vol. 11, no. 10, 1 October 1998 (1998-10-01), pages 1217 - 1222, XP055009782, ISSN: 0893-228X, DOI: 10.1021/tx9801458 *
LAPPIN GRAHAM ET AL: "Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.", NATURE REVIEWS. DRUG DISCOVERY MAR 2003, vol. 2, no. 3, March 2003 (2003-03-01), pages 233 - 240, XP002551693, ISSN: 1474-1776 *
LAPPIN GRAHAM ET AL: "Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry", 20040101; 20040100, vol. 378, no. 2, 1 January 2004 (2004-01-01), pages 356 - 364, XP009073837 *
SARAPA NENAD ET AL: "THE APPLICATION OF ACCELERATOR MASS SPECTROMETRY TO ABSOLUTE BIOAVAILABILITY STUDIES IN HUMANS: SIMULTANEOUS ADMINISTRATION OF AN INTRAVENOUS MICRODOSE OF C-14-NELFINAVIR MESYLATE SOLUTION AND ORAL NELFINAVIR TO HEALTHY VOLUNTEERS", JOURNAL OF CLINICAL PHARMACOLOGY, LIPPINCOTT CO, HAGERSTOWN, MD, US, vol. 45, no. 10, 1 October 2005 (2005-10-01), pages 1198 - 1205, XP009073848, ISSN: 0091-2700 *
TURTELTAUB K W ET AL: "BIOANALYTICAL APPLICATIONS OF ACCELERATOR MASS SPECTROMETRY FOR PHARMACEUTICAL RESEARCH", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, NL, vol. 6, no. 10, 1 January 2000 (2000-01-01), pages 991 - 1007, XP009032292, ISSN: 1381-6128 *

Also Published As

Publication number Publication date
WO2008064138A3 (fr) 2009-01-15
AU2007323782A1 (en) 2008-05-29
JP2010510495A (ja) 2010-04-02
BRPI0719314A2 (pt) 2014-02-04
CA2669864A1 (fr) 2008-05-29
CN101702921A (zh) 2010-05-05
EP2094861A2 (fr) 2009-09-02
WO2008064138A2 (fr) 2008-05-29

Similar Documents

Publication Publication Date Title
GB0602178D0 (en) Therapeutic treatment
GB0606604D0 (en) Treatment apparatus
GB0608655D0 (en) Therapeutic Treatment
IL198663A0 (en) Tissue treatment methods
GB0624874D0 (en) Treatment
GB0714363D0 (en) Treatment apparatus
SI2043944T1 (sl) Obdelovalni stroj
IL193747A0 (en) New therapeutic combinations for the treatment of depression
EP2032131A4 (fr) Procédé de traitement
GB0600692D0 (en) Well treatment
GB0610746D0 (en) Method of treatment
GB2449996B (en) Effluent treatment process
EP2066524A4 (fr) Appareil de traitement d'un enfant en basage
GB0610909D0 (en) Therapeutic treatment
IL197125A0 (en) Drug combinations for treating airway diseases
EP2088862A4 (fr) Méthode de traitement du cancer
GB0718684D0 (en) Treatment method
GB0607952D0 (en) Novel treatment
EP2094861A4 (fr) Processus de traitement thérapeutique personnalisé
EP2182884A4 (fr) Appareil de traitement
GB0712613D0 (en) Therapy or treatment apparatus
ZA200904478B (en) Novel therapeutic use for treating leukaemia
GB0607153D0 (en) Therapeutic Method
GB0625112D0 (en) Apparatus for skin treatment
GB0604460D0 (en) Treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090616

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100217

17Q First examination report despatched

Effective date: 20100610

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140618